Under India's National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), the blood pressure threshold for initiating pharmacotherapy in hypertension management at the sub-centre level is:
- A ≥140/90 mmHg on a single reading
- B ≥140/90 mmHg on two readings on two separate visits (or a single reading ≥180/110 mmHg) ✓
- C ≥160/100 mmHg on two readings on two separate visits
- D Any reading above 130/80 mmHg in diabetic patients
Explanation
Under NPCDCS guidelines, hypertension is confirmed and pharmacotherapy is initiated at a BP of ≥140/90 mmHg on at least two separate visits (two readings per visit, averaged). A single measurement ≥180/110 mmHg qualifies as hypertensive urgency/emergency requiring immediate referral regardless of prior readings. This threshold aligns with the 2023 WHO guidelines for initiation of treatment. The 2017 ACC/AHA guideline lowered the threshold to 130/80 mmHg but India's national programme maintains ≥140/90 mmHg as the treatment threshold to balance population-level feasibility with clinical benefit.
Reference: Park's Textbook of Preventive and Social Medicine, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.